6 GHP Biotechnology & Lifesciences Awards 2026 Development within the oncology biotechnology sector remains one of the most dynamic and promising areas in medicine, yet is also characterised by significant complexity and evolving external pressures. Cancer biology itself is highly complex, and demonstrating both strong efficacy and acceptable safety profiles continues to be a key hurdle across the industry. Antharis Therapeutics is an emerging and impactful player in this field, and has been recognised for its contributions in the Biotechnology and Lifesciences Awards 2026. We spoke with Founder, CEO, and Chairman, Dr. Raphael Pinaud, to learn more. Founded in 2020, Antharis is a multinational biotechnology company focused on developing next-generation monoclonal and bispecific antibodies, and antibody-drug conjugates (ADCs) to treat cancers with high unmet medical needs. The company’s work centres on translating cutting-edge scientific innovation into transformative therapies for patients, leveraging proprietary approaches to antibody engineering and ADC development to create therapeutics that deliver powerful anti-cancer activity while maintaining a strong safety and tolerability profile. As a biotechnology company, Antharis ultimately serves patients and physicians, while operationing within a broad ecosystem that includes partners, contract development and manufacturing organisations, academic institutions, investors, and regulatory authorities. Close collaboration across this ecosystem is essential, ensuring that promising science is efficiently translated from the laboratory into clinical trials and, ultimately, patient care. Antharis’ focus has been shaped by the experience of its leadership and scientific teams across oncology drug development, translational research, and biotech entrepreneurship. “Through years of work in oncology, we recognised persistent gaps in treatment efficacy,” said Dr. Pinaud. “This is particularly evident in solid tumours, where resistance and toxicity often limit patient outcomes. This experience guided our decision to concentrate on next-generation ADC technologies and innovative antibody platforms designed to meaningfully improve therapeutic precision and potency.” The company has made significant strides over the last year, with several long-standing development plans translating into tangible progress. The most significant milestone for Antharis has been the continued advancement of its lead antibody-drug conjugate programme, AT-20, designed to address multiple gastrointestinal cancers for which treatment options remain limited. Following years of platform development, molecule optimisation, and translational research, Antharis is now transitioning into a clinical-stage company, with patients expected to receive AT-20 in upcoming clinical trials this year. Operating within the biotechnology and oncology drug development space requires strict adherence to global regulatory frameworks designed to ensure patient safety, data integrity, and product quality. Antharis complies with regulatory frameworks established by authorities such as the U.S. Food and Drug Administration, the European Medicines Agency, and other international health agencies in jurisdictions where development activities take place. Remaining at the forefront of industry developments requires Antharis to continuously engage with the broader scientific and medical community. The team remains closely connected to academic researchers, clinical investigators, and industry experts advancing the frontiers of oncology and biologics development. Antharis actively monitors scientific publications, emerging clinical data, and evolving regulatory guidance to continuously refine its development strategy. Antharis’ expansive ecosystem enables the team to innovate efficiently and responsibly while continuing to accelerate the path to patient impact. “Oncology drug development is ultimately about improving and extending lives,” Dr. Pinaud told us. “Every strategic decision we make is guided by the goal of delivering therapies that meaningfully improve outcomes for patients facing difficult diagnoses.” This goal will continue to shape the future of Antharis’ operations. The coming period represents a defining chapter for the company, as it transitions from an innovation-driven development organisation into a clinical-stage biotechnology company. The primary focus for 2026 is the successful clinical advancement of lead ADC candidate AT-20. Initiating and executing early clinical studies will be a major milestone, marking the point at which the team’s scientific efforts translate directly into potential patient benefit. At the same time, the team is working to expand its pipeline into the clinic. Antharis’ technology and partnerships position the company to develop additional next-generation ADC candidates, and in 2026 the team expects to continue advancing its leading assets through the final stages of preclinical development, with the goal of maintaining a robust portfolio of oncology therapies in the clinic. “Ultimately, our ambition for 2026 and beyond is clear: to establish Antharis as a recognised clinical-stage oncology innovator capable of delivering multiple differentiated therapies,” concluded Dr. Pinaud. “While drug development timelines require patience and discipline, we believe the progress we are now achieving reflects years of careful groundwork. “In short, this is a story about scientific vision combined with disciplined execution and a deep commitment to patients, and we are excited to contribute meaningfully to the future of oncology care.” Contact: Dr. Raphael Pinaud, PhD/MBA Company: Antharis Therapeutics Web Address: www.antharistherapeutics.com Oncology Biopharmaceutical Company of the Year 2026 & GHP Innovation Excellence Award 2026 Antharis Therapeutics
RkJQdWJsaXNoZXIy MTUyMDQwMA==